Select acadia healthcare hospitals to participate in clinical trial for acute suicidal ideation and behavior in major depression drug
Franklin, tenn.--(business wire)--acadia healthcare company, inc. (nasdaq: achc) today announced that select facilities from its network of acute care behavioral health hospitals will participate in a registration directed trial to study participants with suicidal ideation and behavior with major depression. this study is sponsored by seelos therapeutics (nasdaq: seel) for its sls-002 investigational drug. acadia hospitals that meet the criteria for participation as clinical trial sites will be able to offer enrollment in this study to eligible patients who exhibit specific symptoms and meet the enrollment conditions. “we are pleased that select hospitals from our network will take part in this program given its rigorous and comprehensive requirements,” said dr. michael genovese, m.d., chief medical officer of acadia healthcare. “our acute care behavioral health hospitals strive to provide quality care and innovative treatments. sls-002 has shown promise in part 1 of this trial, and we are hopeful that it can enhance the positive patient outcomes for these at-risk groups.” sls-002 is intranasal racemic ketamine with two investigational new drug applications for the treatment of acute suicidal ideation and behavior in patients with major depression. seelos looks to address an unmet need to treat these conditions in the u.s. with sls-002. the protocol requires a five-dose regimen spread over the first 15 days of treatment (both in-and out-patient) after medical assessment. this is part 2 of the study, which is randomized, double-blind, and placebo controlled. the purpose of the study is to evaluate the efficacy, safety, and tolerability of repeat doses of sls-002 in the target indication. seelos therapeutics, inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (cns) disorders and other rare diseases. about acadia healthcare acadia is a leading provider of behavioral healthcare services across the united states. as of june 30, 2022, acadia operated a network of 239 behavioral healthcare facilities with approximately 10,600 beds in 39 states and puerto rico. with more than 22,500 employees serving approximately 70,000 patients daily, acadia is the largest stand-alone behavioral health company in the u.s. acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
ACHC Ratings Summary
ACHC Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission